Replies to post #280053 on NorthWest Biotherapeutics Inc (NWBO)

[CherryTree1]

It is water under the bridge at this point.
We'll just have to see what happens over then next few months.

[Doc logic]

JerryCampbell,

Seems like FDA guidance has been changing enough with the science over the last 5 years for that round hole to be squared out a bit especially in light of the missing SOC/placebo patients that FDA didn't want to enroll after all planned for treatment patients did. Just sayin : ). Best wishes.

[sentiment_stocks]

The company would still have had to pay for continuing the treatments in this trial (and let’s not forget the 90 or so patients in the expanded access trial) as they would never have stopped treating them, and then would have had to pay for treating all those 400 new patients (and the additional patients who didn’t qualify but whose treatments were also made). They’d already struggled to fund the current trial for 7 years by 2015. Raising the funds for an additional trial to run for another four or five years would have been even more difficult, especially if they’d given up on the current one. They’d have had to take on a partner, I’d think for certain, and I don’t think that was a pathway LP was interested in walking at the time.

[TopelRoad]

One of the agonies of clinical trial design is that the wrong end point can be selected or the trial design can be faulty. NWBO is not the only company that has encountered these issues.

The most conservative approach is always best, it builds trust and keeps patients safe. Integrity matters in this business.